Abstract: Provided herein are combinations of therapeutic agents useful for the treatment of cerebellar ataxia and methods of use thereof. In particular, embodiments herein baclofen and chlorzoxazone are administered for the treatment of cerebellar ataxia.

Abstract: Provided herein are combinations of therapeutic agents useful for the treatment of cerebellar ataxia and methods of use thereof. In particular, embodiments herein baclofen and chlorzoxazone are administered for the treatment of cerebellar ataxia.

Abstract: The present invention is based on the discovery and cloning of two variants of the small conductance calcium activated potassium channel type 3 (hKCa3/KCNN3) gene. The isoform variants are identical to the structure of the SKCa3-1a transcript with regard to exons 2–8, but differ in that one variant, SKCa3-1b, contains exon 1b in place of exon 1a and in that the other variant, SKCa3-1c, contains exon 1c in place of exon 1a. When expressed simultaneously with SKCa3-1a, the variants will independently dominantly negatively suppress SKCa3-1a and other functional members of the SKCa channel family. Accordingly, the present invention provides the novel gene variants, methods for the detection of the variants and treatment of disorders related to the activity of these variants. Kits employing the methods of the invention are also described.

Abstract: Transgenic animals exhibiting several hallmark features of SK-3 related pathologies, including moderate to severe ataxia, intention tremors and hyperexcitable behavior are provided. This transgenic animal model represents a valuable research tool for testing candidate agents for treatment of individuals diagnosed with SK-3 related pathologies, either prophylactically or after disease onset.